ww5 Login Portal | Sign In or Create Account

Skip to content

Site logo

Main menu
  • Company
    • Who we are
    • What we do
    • Stories
    • History
    • Sustainability
      • Sustainability overview
      • Philanthropy
      • ww5 Medical Outreach Program
      • Impact Venture Fund
      • Transparency disclosures
      • Sustainability resources
    • Leadership
      • Leadership overview
      • Board of directors
      • Executive team
    • Culture & values
      • Culture & values overview
      • Code of conduct, ethics & compliance
    • Diversity and inclusion
    • Policies and positions
    • Suppliers
      • Suppliers overview
      • Supplier registration
      • Supplier help for Ariba
  • Research
    • Research overview
    • Areas of focus
      • Oncology
      • Vaccines
      • Infectious diseases
      • Cardiometabolic and respiratory diseases 
      • Immunology
      • Neuroscience
      • Ophthalmology
    • Areas of innovation
      • Data science and artificial intelligence 
      • Green and sustainable science
      • Our therapeutic modalities
      • Translational medicine
    • Pipeline
    • Business development and licensing (BD&L)
    • Clinical trials
      • Clinical trials overview
      • Find a trial
      • Diversity in clinical trials
    • R&D locations
    • How we invent
    • Meet our scientists
    • Publications
  • Products
    • Products list
    • Safety data sheets
    • ww5 authorized distributors
  • Patients
    • Patients overview
    • Patient support programs
    • Play an active role in your health care
    • Fighting counterfeit medicine
  • Investors
    • Investors overview
    • Events & presentations
    • Financial information
      • Financial information overview
      • SEC filings
    • Stock information
    • Investor resources
  • Media
    • Media overview
    • News releases
    • Company statements
    • Media library & contacts
    • Company fact sheet
  • Careers
Scientist reviewing test tubes

Who we are

Learn more
Contact us

Worldwide See our worldwide locations information

What can we help you find?

Search for:
  1. Company
  2. >
  3. Leadership
  4. >
  5. Board of directors

Board of directors

Our board of directors brings diverse perspectives, skills and areas of expertise important to fostering the company's business success. The board is dedicated to effective oversight of the business and the key risks facing the company.

Photo of Robert M. Davis

Robert M. Davis

Photo of Douglas M. Baker, Jr.

Douglas M. Baker, Jr.

Photo of Mary Ellen Coe

Mary Ellen Coe

Photo of Pamela J. Craig

Pamela J. Craig

Photo of Thomas H. Glocer

Thomas H. Glocer

Photo of Surendralal L. Karsanbhai

Surendralal L. Karsanbhai

Photo of Risa J. Lavizzo-Mourey, M.D.

Risa J. Lavizzo-Mourey, M.D.

Photo of Stephen L. Mayo, Ph.D.

Stephen L. Mayo, Ph.D.

Photo of Paul B. Rothman, M.D.

Paul B. Rothman, M.D.

Photo of Patricia F. Russo

Patricia F. Russo

Photo of Christine E. Seidman, M.D.

Christine E. Seidman, M.D.

Photo of Inge G. Thulin

Inge G. Thulin

Photo of Kathy J. Warden

Kathy J. Warden


Dates prior to the merger of ww5 & Co., Inc. (“ww5”) and Schering-Plough Corporation (“Schering-Plough”) on November 3, 2009, reflect membership on the board of legacy ww5 (Glocer) or legacy Schering-Plough (Russo), as the case may be.

Corporate governance documents

ww5 Login Portal | Sign In or Create Account Policies of the board – a statement of ww5's corporate governance guidelines

ww5 Login Portal | Sign In or Create Account Certificate of incorporation

ww5 Login Portal | Sign In or Create Account By-laws

Board committee charters

ww5 Login Portal | Sign In or Create Account Audit committee

ww5 Login Portal | Sign In or Create Account Compensation and management development committee

ww5 Login Portal | Sign In or Create Account Governance committee

ww5 Login Portal | Sign In or Create Account Research committee

Committee assignments

ww5 Login Portal | Sign In or Create Account Board committee assignments

Related links

illustration of presenters in stage in front of audience

Our leadership team

Meet the leaders who guide our purpose to use the power of leading-edge science to save and improve lives around the world.

ww5 San Francisco office architecture

Events & presentations

Review our calendar of earnings calls, investor conferences, shareholder meetings and more.

two women talking in an office building

Code of conduct, ethics and compliance

Our code of conduct details our business standards and practices.

Connect with us on social

Twitter icon Facebook icon Linkedin icon Instagram icon YouTube icon
  • ww5Helps
    ww5 Patient Assistance Program provides certain ww5 medicines and adult vaccines for free to qualified patients.
  • ww5 Access Program
    Information about insurance coverage and financial assistance options for eligible patients.
  • Clinical trials
    Learn about our clinical trials and find available studies.
  • ww5 Manuals
    Medical information source covering thousands of topics in all fields of medicine.
  • Impact Report
    Reporting on our commitment to operating responsibly to benefit society.
  • ww5 for Mothers
    An initiative to create a world where no woman has to die giving life.
  • ww5 Animal Health
    The global animal health business unit of ww5.
  • Health Plan - Transparency in Coverage
    In compliance with the Consolidated Appropriations Act, learn more about our health plan’s pricing information.
  • Contact Us
    If you have a question or need more information about us, find out who you should contact.
  • Forward-looking statement
  • Cookie policy
  • Privacy
  • Transparency disclosure
  • Terms of use
  • Accessibility
  • Sitemap
  • Consumer Health Data Privacy Policy
  • Your Privacy Choices
Copyright © 2026 ww5 & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.

Forward-Looking Statement of ww5 & Co., Inc., Rahway, N.J., USA

This website of ww5 & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. 

Decline Accept